GLP-1 receptor agonists showed no increased risk of bone healing failure (pseudoarthrosis) in diabetic patients undergoing midfoot fusion surgery. Among 1,532 propensity-matched patients over age 40, those using GLP-1RAs within six months before surgery had similar pseudoarthrosis rates at five years compared to non-users (15.0% vs 12.6%). Hardware infections, wound complications, and hardware removal rates were also equivalent between groups. This finding addresses a critical clinical concern as GLP-1 receptor agonists like semaglutide and liraglutide gain widespread adoption for diabetes management and weight loss. Previous animal studies suggested these medications might impair bone metabolism, creating uncertainty about their safety in patients requiring orthopedic procedures. The results are reassuring for the millions using these blockbuster drugs, though the study focuses specifically on diabetic patients and midfoot procedures. The research represents incremental but valuable evidence in the evolving understanding of GLP-1RA effects beyond glucose control. However, the observational design cannot establish causality, and longer-term bone health effects in non-surgical contexts remain unclear. For clinicians, this supports continuing GLP-1RA therapy perioperatively without added bone healing concerns.